(170 Total References)
Emilio A. ...
Emilio A. Emini
Emilio A. Emini, Ph.D., is Senior Vice President of Vaccine Research and Development at Pfizer Inc., a position into which he transitioned subsequent to Pfizer's acquisition of Wyeth Pharmaceuticals in late 2009.
Dr. Emini joined Wyeth as Executive Vice President of Vaccine Research and Development in November 2005.
At Wyeth, he led the R&D efforts that resulted in licensure of Prevnar 13, Pfizer's vaccine for the prevention of pneumococcal disease.
Currently, Dr. Emini leads Pfizer's worldwide vaccine research and development programs.
Dr. Emini joined the pharmaceutical industry in 1983 at the Merck Research Laboratories where he led the biological research that resulted in the development of one of the first highly active antiretroviral therapies for the treatment of HIV infection.
As head of vaccine research at Merck, he participated in a number of vaccine development programs, including those that resulted in the licensure of the human papillomavirus and human rotavirus vaccines.
Prior to joining Wyeth, Dr. Emini also served as Senior Vice President of Vaccine Development at the International AIDS Vaccine Initiative.
Dr. Emini is also an Adjunct Professor of Pathology and Laboratory Medicine at the University of Pennsylvania School of Medicine.
In 2006, he
was awarded the Distinguished Alumnus Award from the Cornell University Graduate School of Medical Sciences
He is a Fellow of the American Academy of Microbiology and a former Trustee of the National Foundation for Infectious Diseases.
Dr. Emini also serves as a member of the National Biodefense Science Board, an advisory committee to the U.S. Secretary of Health and Human Services.
Dr. Emini received his Ph.D. in Microbiology, Genetics and Biochemistry from the Cornell University Graduate School of Medical Sciences.
Emilio Emini, Ph.D., Chief ...
Emilio Emini, Ph.D., Chief Scientific Officer of Vaccine Research at Pfizer, said, "Prevenar 13 has been administered to millions of individuals around the world, and today's European approval for the expanded use of Prevenar 13 is a testament to Pfizer's continued commitment to developing innovative vaccines that can help prevent serious - and sometimes fatal - disease through every stage of life.
Wyeth: Investor Relations: Investor News
Emilio A. Emini, Ph.D., Appointed Executive Vice President, Vaccines Research and Development, Wyeth Pharmaceuticals
...Emilio A. Emini, Ph.D., Appointed Executive Vice President, Vaccines Research and Development, Wyeth Pharmaceuticals MADISON, N.J., Nov. 2 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) announced today the appointment of Emilio A. Emini, Ph.D. as Executive Vice President, Vaccines Research and Development, for Wyeth Pharmaceuticals effective November 7, 2005.Dr. Emini joins Wyeth from the International AIDS Vaccine Initiative (IAVI), where he was Senior Vice President for Vaccine Development.Prior to this position at IAVI, Dr. Emini was Senior Vice President, Vaccines and Biologics Research, with Merck & Co., Inc.
new role, Dr. Emini
will lead an organization of approximately 600 scientists and professional support employees responsible for research and development for Wyeth Vaccines.His
strategic leadership will be focused on research areas that include pneumococcal disease, bacterial meningitis, respiratory diseases, Alzheimer's disease, HIV infection, and sexually transmitted diseases."Dr. Emini brings to his new role a proven record in leading high- quality research organizations at Merck and IAVI.He
is a well-known and highly accomplished vaccine research leader," says Robert R. Ruffolo, Jr., Ph.D., President, Research & Development and Senior Vice President, Wyeth."We are grateful that he
is accepting the challenge to lead Wyeth Vaccines Research and Development to strengthen its position as a leader in our industry."Dr. Emini
will report to Dr. Ruffolo.Following his Ph.D. in Microbiology from Cornell University Graduate School of Medical Sciences in 1980, Dr. Emini was a Postdoctoral Fellow in the Department of Microbiology at the State University of New York at Stony Brook from 1980 to 1983.Dr. Emini then joined the Merck Research Laboratories where he held positions of increasing responsibility in both vaccine and antiviral therapeutic research.For the past 18 months, Dr. Emini has served as the Senior Vice President for Vaccine Development at IAVI where he was responsible for expanding and leading the organization's efforts on HIV vaccine development, and enhancing IAVI's vaccine study infrastructure in countries most affected by the HIV pandemic.Dr. Emini
has authored more than 180 articles in peer-reviewed scientific journals and other medical publications, has edited a book about HIV treatment and research, and holds a number of U.S. and international patents.He is a Fellow of the American Academy of Microbiology.
World-Class AIDS Vaccine Researcher Emilio Emini Joins IAVI :: PNNOnline ::
World-Class AIDS Vaccine Researcher Emilio Emini Joins IAVI
...Emilio A. Emini, Ph.D., a globally recognized expert in AIDS and vaccines, has joined the International AIDS Vaccine Initiative (IAVI) as Senior Vice President and Chief of Vaccine Development.Dr. Emini
will oversee IAVI's
partnership programs to develop a vaccine to prevent HIV infection and AIDS.An effective vaccine is the best hope for stopping the continuing spread of the epidemic.Dr. Emini
joins the nonprofit IAVI after 20 years at Merck & Co., Inc.
, where he
gained recognition as one of the world's preeminent AIDS vaccine scientists.He
is credited for leading the pharmaceutical giant's AIDS vaccine efforts, advancing five different vaccine candidates to human trials.In addition to searching for an AIDS vaccine, Dr. Emini
led the Merck team that developed one of the first highly effective antiretroviral agents for the treatment of people living with HIV.As Merck's Senior Vice President of Vaccine Research, Dr. Emini was responsible for Merck's overall basic vaccine research program including diseases other than AIDS.
brings drive, dedication and experience in large-scale vaccine development from his
distinguished career at a leading pharmaceutical company.He
will help IAVI
navigate the way forward given the complexities of finding an AIDS vaccine."At IAVI, Dr. Emini will work alongside Wayne Koff, Ph.D., who has been appointed Senior Vice President and Chief of Vaccine Research.
will focus on developing these concepts into vaccine candidates that are tested in human trials, and accelerating the most promising to large-scale efficacy trials and eventual licensure.
brings his extensive vaccine development skills to the challenges of improving upon the current portfolio of candidates, and together with Dr. Koff will lead the effort to design, develop and test the next generation of candidates.
..."World-Class AIDS Vaccine Researcher Emilio Emini Joins IAVI" | Login/Create an account | 0 Comments
Emilio Emini, senior vice ...
Emilio Emini, senior vice president of vaccine research and development at Pfizer, explained that, shortly after the outbreak at the University at the end of 2013, the FDA asked Pfizer if the company felt it had sufficient data to apply for accelerated approval.
explained that Trumenba had been in research and development for over 10 years.
added that serogroup B was the only serogroup not covered by existing vaccines and that many cases of meningitis B had been reported over the years.
"Obviously, you had the outbreak in Princeton last year, and after that, you saw it reported more in the news, but serogroup B cases are reported all the time," Emini
explained that shortly after the outbreak at the University at the end of 2013, the FDA
if the company felt that it had sufficient data to apply for accelerated approval.
felt that its data had met the requirements, it decided to apply.
explained that the vaccine specifically targets individuals between the ages of 10 and 25, since a majority of the cases involving this disease have been identified in adolescents and young adults.
added that the meningococcal bacterium is typically transmitted among adolescents and young adults and that this age group is also largely responsible for transmitting the disease to other people.
Older adults and young infants, who also tend to be more vulnerable to the disease, typically receive the bacterium through transmission from adolescents and young adults, Emini